Kobayashi Pharma stock at JPY 7,283.00 on October 16, 2026, 1.42 percent below high

Published on 10/17/2026 at 19:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts averaged JPY 5,279.96 on October 12, 2026. Kobayashi Pharma stock cost JPY 7,283.00 on October 16, 2026, down 0.51 percent in Tokyo.

Stock stays near yearly high

A 12-analyst consensus averaged JPY 5,279.96 on October 12, 2026.
Kobayashi Pharmaceutical had a market capitalization of JPY 541.4 billion on October 16, 2026.
Kobayashi Pharma stock was JPY 7,283.00 in Tokyo on October 16, 2026 at 3:30 p.m. JST, down 0.51 percent versus the prior close.

Kobayashi Pharma, JP3301100008, Illustration mit AI erstellt.

A 12-analyst consensus placed Kobayashi Pharmaceutical's average target at JPY 5,279.96 on October 12, 2026, according to Eulerpool. The target stood 27.51 percent below the latest Tokyo price. Kobayashi Pharma stock was JPY 7,283.00 in Tokyo on October 16, 2026 at 3:30 p.m. JST, down 0.51 percent from the prior close and 1.42 percent below its JPY 7,388.00 52-week high.

Consensus target stays below price

The valuation gap is the clearest market signal outside the daily move. The average target of JPY 5,279.96 compares with the JPY 7,283.00 closing price, while the consensus covers 12 analyst ratings. Eulerpool reported a median target of JPY 5,314.20 and an overall Hold consensus on October 12, 2026.

Price position remains elevated

Kobayashi Pharma finished the latest Tokyo session only 1.42 percent below its 52-week high of JPY 7,388.00. Its 52-week low was JPY 5,030.00, leaving a spread of JPY 2,358.00 between the recorded extremes. The stock's latest price was 44.79 percent above that low.

The company also carried a market capitalization of JPY 541.4 billion on October 16, 2026. Its trailing price-to-earnings ratio was 333.01, while the dividend yield was 0.01 percent. These figures put the stock's market valuation well above the two consumer-product peers used for comparison below.

Comparison with peers

Kobayashi Pharma (Tokyo, JPY): minus 0.51 percent, P/E 333.01, market capitalization JPY 541.4 billion

Rohto Pharmaceutical (Tokyo, JPY): plus 1.50 percent, P/E 20.99, market capitalization JPY 665.8 billion

Lion Corporation (Tokyo, JPY): plus 1.65 percent, P/E 18.09, market capitalization JPY 521.2 billion

What the valuation leaves investors

The comparison points to a stock trading near its yearly peak while carrying a much higher trailing P/E than Rohto Pharmaceutical and Lion Corporation. The 12-analyst target also remains below the latest Tokyo price, making the distance between market price and published expectations the central valuation metric.

Kobayashi Pharmaceutical develops and sells over-the-counter medicines, health products, household goods and personal-care products. The company is listed in Tokyo under ticker 4967.T, with its latest reported market figures dated October 16, 2026.